Latest Telehealth News

Vitura Health’s joint venture Flora Holdings has acquired Heyday Medical Clinic, a leading medicinal cannabis provider, enhancing its national clinical network and patient access across Australia.

MedAdvisor Solutions reported a challenging third quarter with steep revenue declines, driven by delayed program launches and US sales underperformance, but is executing a strategic overhaul and cost-cutting measures to position for a rebound and 15% revenue growth in FY26.

Vitasora Health Limited reports a striking 101% revenue increase and 57% patient growth in Q1 2025, driven by new Medicare Shared Savings Plan contracts and significant operational efficiencies from its Orb Health merger.

LTR Pharma reports strong Q1 2025 progress with FDA pre-IND meeting success, scientific acclaim for SPONTAN’s rapid absorption, and strategic launch of ROXUS to fast-track US market entry.

Vitura Health Limited has acquired Candor Medical, a leading Australian medicinal cannabis clinic, for $5.9 million, significantly boosting its digital health platform and patient base.

Vitura Health has raised $5.1 million from prominent investor Professor Khalil Shahin, marking a significant step towards acquiring Candor Medical and accelerating its digital health expansion.

Advanced Health Intelligence Ltd (AHI) has secured USD 4 million in convertible debt funding and launched two new commercial partnerships in Canada and the UK, marking significant progress despite its ongoing ASX trading suspension.

Epsilon Healthcare's December 2023 quarterly report reveals significant boardroom conflict and governance breaches, yet operational segments show promising growth.

Botanix Pharmaceuticals has initiated the commercial rollout of Sofdra, its FDA-approved treatment for primary axillary hyperhidrosis, with first prescriptions dispensed and a fully trained sales force deployed. The company anticipates meaningful revenue growth starting in the first quarter of 2025, backed by strong payer contracts and a robust cash position.

LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.

Doctor Care Anywhere delivered positive cash flow and revenue growth at the top of guidance in Q4 2024, while navigating a strategic shift with new leadership appointments and the closure of secondary care pathways.